CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.
Learn about CG0070
Cretostimogene grenadenorepvec (CG0070) is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.
CG Oncology by the Numbers.
3
Active clinical programs
with planned studies soon underway. See current clinical trials.
88%
Complete response rate
at any time for CG0070 in combination with KEYTRUDA®
73%
Complete response rate
at 12 months for CG0070 in combination with KEYTRUDA®
Investors
